HGEN RSI Chart
Last 7 days
0.9%
Last 30 days
30.5%
Trailing 12 Months
38166.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 1.7M | 0 | 0 | 0 |
2022 | 4.1M | 4.1M | 3.3M | 2.5M |
2021 | 1.1M | 2.0M | 2.8M | 3.6M |
2020 | 0 | 0 | 0 | 0 |
2019 | 0 | 0 | 0 | 0 |
2018 | 0 | 0 | 0 | 0 |
2017 | 0 | 0 | 0 | 0 |
2016 | 0 | 0 | 0 | 0 |
2015 | 0 | 0 | 0 | 29.0K |
2013 | 4.6M | 3.1M | 1.6M | 44.0K |
2012 | 19.0M | 17.7M | 11.9M | 6.1M |
2011 | 18.3M | 19.0M | 19.6M | 20.3M |
2010 | 0 | 0 | 0 | 17.7M |
2009 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 18, 2023 | chappell dale | sold | -376 | 0.011 | -34,253 | chief scientific officer |
Oct 18, 2023 | chappell dale | sold | -834 | 0.011 | -75,887 | chief scientific officer |
Oct 18, 2023 | chappell dale | sold | -3,038 | 0.011 | -276,210 | chief scientific officer |
May 20, 2022 | chappell dale | bought | 243,070 | 2.228 | 109,098 | chief scientific officer |
May 20, 2022 | chappell dale | bought | 850,742 | 2.228 | 381,841 | chief scientific officer |
May 20, 2022 | chappell dale | bought | 121,535 | 2.228 | 54,549 | chief scientific officer |
May 19, 2022 | chappell dale | bought | 70,784 | 2.186 | 32,381 | chief scientific officer |
May 19, 2022 | chappell dale | bought | 141,570 | 2.186 | 64,762 | chief scientific officer |
May 19, 2022 | chappell dale | bought | 495,490 | 2.186 | 226,665 | chief scientific officer |
May 18, 2022 | chappell dale | bought | 34,079 | 1.962 | 17,370 | chief scientific officer |
Which funds bought or sold HGEN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Triumph Capital Management | unchanged | - | -17.00 | 3.00 | -% |
Feb 14, 2023 | Telemetry Investments, L.L.C. | reduced | -6.00 | -34,000 | 56,000 | 0.09% |
Nov 14, 2022 | Corient Capital Partners, LLC | unchanged | - | - | 19,000 | -% |
Aug 15, 2022 | Frontier Wealth Management LLC | unchanged | - | -47,000 | 108,000 | 0.01% |
May 16, 2022 | Amalgamated Financial Corp. | new | - | 24,000 | 24,000 | -% |
May 16, 2022 | Parametric Portfolio Associates LLC | new | - | 92,000 | 92,000 | -% |
Nov 15, 2021 | Marshall Wace North America L.P. | sold off | -100 | -3,891,000 | - | -% |
Unveiling Humanigen, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Humanigen, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.91 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.68 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.3 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.27 | 14.48 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Humanigen, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | 0% | 221,000 | 221,000 | 221,000 | 1,036,000 | 1,036,000 | 1,037,000 | 1,036,000 | 1,036,000 | 486,000 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | 209.3% | 4,456,000 | -4,076,000 | 22,942,000 | 30,387,000 | 21,565,000 | 33,382,000 | 67,015,000 | 71,088,000 | 64,882,000 | 32,607,000 | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 12.7% | 3,719,000 | 3,301,000 | 4,013,000 | 3,949,000 | 4,345,000 | 4,024,000 | 6,204,000 | 8,076,000 | 4,948,000 | 4,112,000 | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | 110.0% | 737,000 | -7,377,000 | 18,929,000 | 26,438,000 | 17,220,000 | 29,358,000 | 60,811,000 | 63,012,000 | 59,934,000 | 28,495,000 | - | - | - | - | - | - | - | - | - | - | - |
EBITDA Margin | -102.3% | -0.01 | 0.28 | 0.40 | 0.19 | 0.18 | 0.01 | -0.25 | -0.74 | -1.12 | -2.81 | -18.31 | -6.59 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -84.7% | 18,000 | 118,000 | 1,298,000 | 768,000 | 734,000 | 748,000 | 751,000 | 746,000 | 19,000 | - | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -48.0% | -1.31 | -0.89 | -0.67 | -0.54 | -0.54 | -0.62 | -0.80 | -1.14 | -1.97 | -7.15 | -76.97 | -76.97 | - | - | - | - | - | - | - | - | - |
Net Income | -195.3% | -4,182,000 | 4,390,000 | -23,693,000 | -30,149,000 | -21,278,000 | -33,540,000 | -66,739,000 | -70,803,000 | -65,567,000 | -32,295,000 | - | - | - | - | - | - | - | - | - | - | - |
Net Income Margin | -12.2% | -31.57 | -28.13 | -32.63 | -36.60 | -46.41 | -65.83 | -84.85 | -102 | -134 | -286 | -2,043 | -1,065 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 51.6% | -7,059,000 | -14,570,000 | -17,309,000 | -25,377,000 | -19,442,000 | -32,259,000 | -48,002,000 | -67,960,000 | -35,824,000 | -23,695,000 | -23,543,000 | -22,007,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Assets | -54.3% | 5.00 | 11.00 | 26.00 | 49.00 | 71.00 | 71.00 | 78.00 | 122 | 99.00 | 68.00 | 92.00 | 43.00 | 29.00 | 15.00 | 1.00 | 2.00 | 1.00 | 1.00 | 3.00 | 1.00 | 3.00 |
Current Assets | -54.7% | 5.00 | 11.00 | 26.00 | 49.00 | 71.00 | 71.00 | 78.00 | 122 | 99.00 | 68.00 | 92.00 | 42.00 | 0.00 | 0.00 | 1.00 | 2.00 | 1.00 | 1.00 | 3.00 | 1.00 | 2.00 |
Cash Equivalents | -69.5% | 3.00 | 10.00 | 25.00 | 47.00 | 69.00 | 70.00 | 77.00 | 121 | 93.00 | 68.00 | 91.00 | 42.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 1.00 | 2.00 | 0.00 | 2.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 |
Liabilities | -5.4% | 55.00 | 58.00 | 78.00 | 100 | 96.00 | 95.00 | 96.00 | 78.00 | 82.00 | 23.00 | 15.00 | 11.00 | 17.00 | 15.00 | 13.00 | 12.00 | 10.00 | 9.00 | 9.00 | 8.00 | 8.00 |
Current Liabilities | -5.2% | 53.00 | 56.00 | 76.00 | 77.00 | 71.00 | 69.00 | 69.00 | 50.00 | 53.00 | 20.00 | 15.00 | 11.00 | 15.00 | 14.00 | 10.00 | 10.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 |
Long Term Debt | - | - | - | - | 23.00 | 25.00 | 25.00 | 25.00 | 25.00 | 24.00 | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Current | - | - | - | - | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | 23.00 | 25.00 | 25.00 | 25.00 | 25.00 | 24.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | - | - | - | - | - | - | - | - | 44.00 | 17.00 | 46.00 | 77.00 | 32.00 | - | - | - | - | - | - | - | - | - |
Retained Earnings | -0.6% | -685 | -681 | -686 | -662 | -632 | -611 | -577 | -510 | -440 | -374 | -342 | -311 | -287 | -284 | -282 | -280 | -277 | -274 | -272 | -270 | -267 |
Additional Paid-In Capital | 0.2% | 636 | 635 | 634 | 612 | 607 | 587 | 560 | 554 | 457 | 420 | 419 | 343 | 271 | 271 | 270 | 270 | 267 | 266 | 266 | 263 | 262 |
Shares Outstanding | 0% | 119 | 119 | 119 | 71.00 | 66.00 | 64.00 | 59.00 | 56.00 | 53.00 | 52.00 | 32.00 | 27.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 84.00 | - | - | - | 711 | - | - | - | 370 | - | - | - | 48.00 | - | - | - | 28.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Cashflow From Operations | 51.6% | -7,059 | -14,570 | -17,309 | -25,377 | -19,442 | -32,259 | -48,002 | -67,960 | -35,824 | -23,695 | -23,543 | -22,007 | -607 | -549 | -1,179 | -1,589 | -684 | -1,224 | -1,254 | -1,903 | -1,828 |
Share Based Compensation | -2.2% | 1,222 | 1,250 | 1,382 | 1,635 | 1,543 | 1,553 | 1,434 | 1,871 | 510 | 476 | 1,012 | 357 | 265 | 148 | 451 | 729 | 697 | 642 | 715 | 780 | 2,675 |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | - | - | - | -5,012 | 3,475 | 18,374 | 25,775 | 3,966 | 95,604 | 60,979 | 1.00 | 73,265 | 63,668 | 532 | 535 | 245 | 2,500 | 50.00 | - | 3,025 | 580 | 2,651 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue: | ||
Total revenue | $ 221 | $ 1,036 |
Operating expenses: | ||
Research and development | 737 | 17,220 |
General and administrative | 3,719 | 4,345 |
Total operating expenses | 4,456 | 21,565 |
Loss from operations | (4,235) | (20,529) |
Other income (expense): | ||
Interest expense | (18) | (734) |
Other income (expense), net | 71 | (15) |
Net loss | $ (4,182) | $ (21,278) |
Basic net loss per common share (in Dollars per share) | $ (0.04) | $ (0.32) |
Weighted average common shares outstanding used to calculate basic net loss per common share (in Shares) | 119,080,135 | 65,590,724 |
License revenue | ||
Revenue: | ||
Total revenue | $ 221 | $ 1,036 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,096 | $ 10,155 |
Prepaid expenses and other current assets | 1,930 | 950 |
Total current assets | 5,026 | 11,105 |
Other assets | 90 | 90 |
Total assets | 5,116 | 11,195 |
Current liabilities: | ||
Accounts payable | 38,392 | 40,520 |
Accrued expenses | 14,021 | 14,791 |
Deferred revenue | 883 | 883 |
Total current liabilities | 53,296 | 56,194 |
Non-current liabilities: | ||
Deferred revenue | 1,545 | 1,766 |
Total liabilities | 54,841 | 57,960 |
Stockholders’ deficit: | ||
Common stock, $0.001 par value: 225,000,000 shares authorized at March 31, 2023 and December 31, 2022; 119,080,135 shares issued and outstanding at March 31, 2023 and December 31, 2022 | 119 | 119 |
Additional paid-in capital | 636,147 | 634,925 |
Accumulated deficit | (685,991) | (681,809) |
Total stockholders’ deficit | (49,725) | (46,765) |
Total liabilities and stockholders’ deficit | $ 5,116 | $ 11,195 |